PrEP

W. David Hardy, MD, discusses the Undetectable Equals Untransmittable (U=U) movement.

A new assay distinguishes between intact and defective HIV proviruses in infected cells, a study reports.

Ian Frank, MD, discusses the future of HIV prevention and long-acting injectables.

W. David Hardy, MD, discusses how important access to PrEP is for people at high risk of contracting HIV.

Ian Frank, MD discusses how younger individuals who do not take regular medication may struggle to adhere to the daily routine.

Concerns of at-risk patients forgoing condoms may be driving the reluctance of some clinicians to prescribe the preventive regimen.

A new study finds that regular use of tenofovir gel helped reduce the risk of genital herpes acquisition in women in sub-Saharan Africa.

W. David Hardy, MD, discusses the challenges health care providers encounter when it comes to patients taking PrEP.

Ian Frank, MD, discusses strategies that individuals taking PrEP can use to maintain adherence to the daily regimen.

A breakthrough message for patients that must be delivered correctly by health care providers. The Undetectable Equals Untransmittable, or U=U, move­ment is a global campaign definitively stating that people living with HIV (PLWH) who have undetectable HIV RNA are unable to transmit HIV. By educating people, the hope is that they will get tested and, if necessary, start and stay on treatment. This message has been endorsed by many organizations, including the US Centers for Disease Control and Prevention and the HIV Medicine Association.

The NIH has announced that a trial evaluating the safety of and adherence to a vaginal ring containing dapivirine and oral tablets for PrEP is now underway in southern Africa.

Targeted marketing of PrEP has unintended consequences that could be avoided with improved messaging, a commentary in The Lancent says.

For individuals willing to self-collect specimens, staying on PrEP in order to avoid HIV infection may get significantly easier.

Taking pre-exposure prophylaxis does not appear to lower the quality of life for people at risk of contracting HIV.

Patients who believe themselves to be at a high risk of contracting HIV are more likely to accept pre-exposure prophylaxis (PrEP) than their peers. That’s one key finding from a new study that looked at how individual factors affect PrEP uptake.

A new study identifies several easy-to-adopt strategies that can help individuals to remember to take PrEP at roughly the same time every day.

Mutual of Omaha will no longer deny coverage to individuals using PrEP for HIV prevention following allegations of discrimination in 2 separate legal settlements.

Investigators on a new study found that the media was both complicit in increasing stigma around pre-exposure prophylaxis (PrEP), and helpful in reducing it as an impediment to its use for HIV prevention.

When combination antiretroviral therapy does not lead to sufficient HIV suppression, a new study finds that PrEP can become cost-effective for couples with differing HIV status who are trying to conceive.

Maraviroc’s safety profile makes it a potential drug of choice for those at risk of contracting HIV, but a recent study raises questions about how well it works.

While the United States has seen significant increases in pre-exposure prophylaxis (PrEP) use among those at risk for HIV infection, PrEP uptake rates are still low overall in men who have sex with men, as well as in transgender individuals. A new study examines how a behavior model may help increase PrEP use in these at-risk groups.

When taken consistently, PrEP can reduce the risk of HIV infection by 92%. So why aren’t more health care professionals prescribing it to adolescents, who continue to have an increased HIV incidence rate nationally?

Clinicians who ask the right questions of patients can help identify those at risk of contracting HIV and who might benefit from PrEP.

On December 1, 2018, international health organizations reflected on the advancements of the HIV/AIDS research field and acknowledged the challenges that still remain such as treating comorbidities and confronting stigma.

Draft guidance effectively outlines what infectious disease specialists have known for years—and leaves many unanswered questions.

The results of a new study demonstrate that PrEP can reduce new infections within a population even when the risk of HIV remains high and other proven treatment and prevention strategies are optimized.

Three new trials, published in CID, highlight potential for intravaginal rings.

As millennials communicate extensively by text, investigators designed a study to improve rates of retention and medication adherence in young men who have sex with men.

Douglas Krakower, MD, explains how predictive models can be used to identify patients that are at a higher risk for HIV and could benefit from learning about PrEP.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.